Literature DB >> 7371690

Combined chemotherapy and radiotherapy for locally advanced breast cancer.

R D Rubens, S Sexton, D Tong, P J Winter, R K Knight, J L Hayward.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7371690     DOI： 10.1016/0014-2964(80)90352-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  22 in total

1.  Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience.

Authors:  E H Koh; A U Buzdar; F C Ames; S E Singletary; M D McNeese; D Frye; F A Holmes; G Fraschini; V Hug; R L Theriault
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  The management of nonmetastatic locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery.

Authors:  R A Sorace; C S Bagley; A S Lichter; D N Danforth; M W Wesley; R C Young; M E Lippman
Journal:  World J Surg       Date:  1985-10       Impact factor: 3.352

3.  Toxicity of intra-arterial doxorubicin in locally advanced breast cancer.

Authors:  C J Twelves; M A Chaudary; J Reidy; M A Richards; R D Rubens
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Neoadjuvant chemotherapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) or cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in 69 cases of locally advanced (stage IIIb) breast cancer.

Authors:  P Gupta; L Bijlani; G K Rath; A Misra; M C Mishra; N K Shukla; A Kriplani; B M Kapur
Journal:  Jpn J Surg       Date:  1991-11

5.  Combined modality treatment of locally advanced breast cancer: adjuvant combination chemotherapy with and without doxorubicin.

Authors:  E S Casper; C A Guidera; G J Bosl; T B Hakes; R J Kaufman; B Shurgot; D W Kinne
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

6.  T3b-T4 breast cancer: factors affecting results in combined modality treatments.

Authors:  P Valagussa; M Zambetti; P Bignami; M de Lena; M Varini; R Zucali; D Rovini; G Bonadonna
Journal:  Clin Exp Metastasis       Date:  1983 Apr-Jun       Impact factor: 5.150

Review 7.  When and how do I use neoadjuvant chemotherapy for breast cancer?

Authors:  Bernardo L Rapoport; Georgia S Demetriou; Shun D Moodley; Carol A Benn
Journal:  Curr Treat Options Oncol       Date:  2014-03

8.  The diagnostic performance of CESM and CE-MRI in evaluating the pathological response to neoadjuvant therapy in breast cancer: a systematic review and meta-analysis.

Authors:  Sudan Tang; Chunhong Xiang; Quan Yang
Journal:  Br J Radiol       Date:  2020-07-02       Impact factor: 3.039

9.  Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.

Authors:  Larissa A Korde; Mark R Somerfield; Lisa A Carey; Jennie R Crews; Neelima Denduluri; E Shelley Hwang; Seema A Khan; Sibylle Loibl; Elizabeth A Morris; Alejandra Perez; Meredith M Regan; Patricia A Spears; Preeti K Sudheendra; W Fraser Symmans; Rachel L Yung; Brittany E Harvey; Dawn L Hershman
Journal:  J Clin Oncol       Date:  2021-01-28       Impact factor: 44.544

10.  Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy.

Authors:  Jie Dong; Qingqing Sun; Yueyin Pan; Nannan Lu; Xinghua Han; Qiong Zhou
Journal:  BMC Cancer       Date:  2021-06-14       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.